PRODUCT

What is Nimotuzumab?

Nimotuzumab is a humanised monoclonal antibody that is being investigated for its binding to the epidermal growth factor receptor (EGFR), a known regulator in oncogenic signalling pathways. Preclinical studies have analysed the extent to which nimotuzumab can selectively bind to cells with high EGFR expression, with the aim of sparing normal tissue as much as possible.
EGFR-targeted therapeutic approaches, including nimotuzumab, are currently being scientifically investigated in combination with established treatment methods such as chemotherapy and radiotherapy. The use of nimotuzumab as a monotherapy or in combination with other treatment modalities is the subject of ongoing research projects.

Anti Cancer properties of Nimotuzumab
  • Antiproliferative activity
  • Antiangiogenic activity
  • Pro-apoptotic activity
  • Mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) activity
  • Radiosensitizing activity
Current regulatory status

Nimotuzumab is an investigational drug that is still in development and has not been authorised for commercial use in Europe. In certain countries, access can be granted under defined conditions as part of named patient programmes. Availability is subject to the respective national regulations.

Named Patient Program

Access via the named-patient basis is only possible if:

  • no suitable authorised treatment options are available for the patient in question,
  • the attending physician recognises a medical necessity and justifies the use on an individual basis,
  • the legal framework of the respective country permits this.

The decision on possible provision is the responsibility of the competent national authorities and is subject to the respective legal requirements. The medical application is made independently, taking into account the individual clinical situation and current scientific knowledge.

Important note
This Information for healthcare professionals is for information purposes only. Patients should contact their treating physician with questions about the availability of nimotuzumab or other treatment options.